paclitaxel + vinorelbine

The combination of paclitaxel and vinorelbine is a chemotherapy regimen used primarily in the treatment of metastatic breast cancer, especially in patients previously treated with anthracyclines. Both drugs are microtubule-targeting agents but have opposite mechanisms of action—paclitaxel promotes microtubule assembly and stabilization, while vinorelbine inhibits microtubule formation. This dual mechanism results in synergistic antitumor activity, particularly against breast cancer cells[2][3][1]. The combination has also been investigated for non-small cell lung cancer (NSCLC) with some efficacy observed[2]. The regimen is generally well tolerated, with main toxicities including myelosuppression (neutropenia), alopecia, and peripheral neuropathy[1][6].

Brand names

TaxolNavelbine

Other names

paclitaxel and vinorelbineTaxol and Navelbine